Parkinson's Disease Clinical Trial
Official title:
A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease
This study will compare two types of assistive devices for communication (a voice amplifier and a personal communication system) in individuals with a speech disorder related to Parkinson's disease. The performance of these two devices will be examined with measures of speech intelligibility and patient questionnaires and rating scales.
The proposed study will involve a comparison of 2 types of communication devices that are
approved for use in individuals with communication disorders. One of the devices, the voice
amplifier, is frequently prescribed for individuals with Parkinson's disease and should be
considered as part of the standard care for the symptom of low speech intensity in this
disorder. The other device is frequently prescribed for individuals with hearing impairment
(unrelated to Parkinson's disease) but is not considered to be part of the standard of care
for individuals with Parkinson's disease. This clinical study will use a crossover design in
which the participants will receive both devices, one after the other, and the order will be
randomized across the individuals. There is no control group or placebo.
This study will include three groups of participants: 1) a PD participant group (n=20), 2) a
communication partner (CP) group (n=20), and 3) a naïve listener group (n=10). The PD
participant group will be comprised of individuals who have mild to moderate signs and
symptoms of idiopathic PD and hypophonia as confirmed by a neurologist. For all individuals
with PD, the speech testing will occur approximately one hour after taking their
antiparkinsonian medication according to their regular medication schedule. The communication
partner group will consist of individuals who regularly converse with the PD participant
(i.e. spouse or primary caregiver). The naive listener group will consist of students from
Western University. The participants with PD will wear a head-set microphone (AKG c520). The
speech intensity of the participants with PD will be calibrated with a sound level meter
(Luton SL-4001) placed 15cm from the mouth while the participant produces a steady 70dB A
prolonged "ah" for about 2 seconds. Two additional tripod-mounted microphones (Shure SM48)
will be placed 2 meters and 4 meters from the PD participant. The communication partner
participants will be seated approximately 30cm from these two microphones during the 2 and 4
meter interlocutor distance conditions. The output from the 3 microphones will be connected
to preamplifiers and a digitizing unit (M-Audio MobilePre) attached via a USB connection to a
PC computer running Praat recording and analysis software (Boersma & Weenink, 2013). An
additional, fourth input line will be attached to the digitizing unit from the output of the
personal communication system when this device is being used in the study. All four audio
signals will be digitized at 44.1 kHz and 16 bits and stored as uncompressed .wav audio
files. The voice amplifier and personal communication system will be evaluated in random
order across the participants. The voice amplifier will be a ChatterVox. This amplifier
includes a headset microphone wired to a speaker/amplifier unit that is worn on a waist belt.
The ChatterVox was selected because it is a typical type of voice amplifier that is
frequently recommended and prescribed to individuals with PD in Ontario. Despite the paucity
of published voice amplifier studies of PD, the ChatterVox has been used in several published
studies of non-neurological voice disorders such as studies of elementary school teachers
with occupational-related voice problems (McCormick & Roy, 2002; Roy et al. 2003). In
addition, a recent MSc thesis conducted at Western University by Monika Andreetta (supervised
by Professor Scott Adams) found that the ChatterVox was one of the best performing and
preferred devices in participants with PD when it was compared to 6 other voice amplifiers.
The personal communication system that will be evaluated is the Easy Listener FM system
(Phonic Ear Corp.). This system includes a light-weight, pocket-sized (2.5 x 9.4 x 5.6 cm; 80
grams) transmitter unit with a head-set microphone and a nearly identical, pocket-sized
receiver unit with a set of small headphones. These units can be carried in a breast-pocket
or attached to a waist-belt with a clip. The transmitter and receiver units are wireless and
communicate via an FM signal. The communication range of the units is approximately 30
meters. The PD participant will wear the transmitter/microphone unit and the communication
partner (CP) participant will wear the receiver/headphone unit. While there are several
personal communication systems that are available, the Easy Listener personal communication
system has been frequently prescribed and has been used in several previous studies of
individuals with hearing impairment (Schafer & Thibodeau, 2004). During some of the
experimental conditions the PD and CP participants will be presented with 65dB A of
multi-talker noise (using a standard Audiotec Corp. Recording of 4-talker noise). The noise
will be presented from a computer via an audio amplifier and loudspeaker placed at 2 meters
from the participants. A sound level meter will be used to calibrate the noise level from the
loudspeaker. Procedures: Speech Tasks: Once one of the two devices has been attached to the
participant(s), the PD participant will be given a list of 6 sentences that were randomly
generated from the Sentence Intelligibility Test software. The PD participant will read aloud
each sentence and then pause while the communication partner (CP) participant attempts to
repeat aloud the sentence. The SIT provides intelligibility measures, which are commonly used
to document effectiveness in intervention programs or outcome studies (Beukelman et al.,
2007). Furthermore, most of the supportive research for the SIT was completed with dysarthric
speakers (Beukelman et al., 2007). After the list of 6 sentences are completed the PD
participant will be given several pictures of people engaged in various activities (i.e.
fishing, playing baseball, doing dishes, etc.) and the PD participant will make statements
that describe the pictures while the CP participant repeats aloud each of these statements.
This will continue until 6 statements (minimum of 5 words each) have been produced/repeated.
Speech Conditions: The speech tasks will be repeated with no device and while using each of
the two devices (ChatterVox voice amplifier and Easy Listener personal communication system)
in two noise conditions (none and 65dB multi-talker noise) and two interlocutor distances (2
and 4 meters). These conditions will be randomized. Rating Scale Procedures: Immediately
following the speech tasks the PD and CP participants will be asked to rate their experience
with the devices using visual analogue scales related to the following five parameters: 1.
Physical comfort: uncomfortable versus comfortable 2. Visual presentation: unacceptable
versus acceptable 3. Sound quality: poor sound quality versus good sound quality 4.
Amplification power: poor amplification versus good amplification 5. Overall preference: low
preference versus high preference The PD and CP participants will use the five visual
analogue scales to provide separate ratings for each of the two devices. Following the
completion of the rating scales the participants will be encouraged to provide additional
feedback about their impressions of the 2 devices. One Week Trial Periods: After the
completion of the lab-based speech and rating scale procedures the PD and CP participants
will be given instructions on the care and use of one of the two devices (i.e. recharging,
cleaning, volume adjustments, attachment, positioning, etc.) and then take the device home
for a one week trial period. The participants will be asked to use the device as often as
they desire but to use the device at least 3 times for a periods of at least one hour over
the course of the week. The participants will be given a Device Use Diary to write down the
dates, times, volume settings and contexts that they used the devices. The participants will
return after one week and complete questionnaires and rating scales related to their
experience and evaluation of the device. These will include the following: 1. Visual analogue
scales related to physical comfort, visual presentation, sound quality, amplification power,
and overall preference. 2. Speech Amplification Satisfaction Scale 3. Quebec User Evaluation
of Satisfaction with Assistive Technology Scale 4. Psychosocial Impact of Assistive Devices
Scale (PIADS). Following the completion of these questionnaires and ratings scales, the
participants will be given instructions on the use and care of the second device and then
take the device home for another one week trial period. The participants will be asked to use
the device as often as they desire but to use the device at least 3 times for a periods of at
least one hour over the course of the week. The participants will be given a Device Use Diary
to write down the dates, times, volume settings and contexts that they used the devices. The
participants will return after one week and again complete the previously described
questionnaires and rating scales related to their experience and evaluation of the device.
Listening Tasks: Listener participants will listen to pre-recorded speech samples obtained
from the tripod-mounted microphones. Speech samples will be played in a randomized order.
Listeners will not be present at the time speech samples are recorded, and they will be
blinded to all information about the speakers and to the contents of the sentences from both
the SIT and picture description tasks prior to hearing them. Listeners will be seated at a
comfortable distance from a loudspeaker, which will be fixed at a comfortable predetermined
volume, and they will be asked to transcribe the data orthographically on prepared forms that
will be numbered to match the presentation order of the stimuli. The SIT software will
compute an intelligibility score by comparing transcribed words and sentences to the stimuli
on the master lists. For the picture description task, sentences will be transcribed
independently by the assessor and then compared to the listeners' transcriptions to determine
the intelligibility score.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 |